Cancer name Glioblastoma
Cancer Type GBM
Immunotherapy type Oncolytic viruses
Treatment H-1PV(oncolytic H-1 parvovirus)
Drugstatus NA
Drugbank ID NA
Checkpoints NA
Signature Type Gene
Signature NH-1PV
Official Symbol NA
Mode of action TRAN_D_UP
Description for ‘mode of action’:the ‘mode of action’ for signature is composed of three parts: A_B_C. A describes the level at which the corresponding signature changes, it may contain the following values: TRAN(translation), PROT(protein), CE(cell), METH(methylation), AC(acetylation), PHOS(phosphorylation), MU(mutation), SNP(single nucleotide polymorphism), GLYC(glycosylation) and PATH(pathway). B describes the corresponding signature in which cancer immunotherapy condition group has changed, it may contain the following values: R (immunotherapy response group), NR(immunotherapy non-response group), D (Immunotherapy group), ND (No immunotherapy group). C describes the change detail (specific direction) of the corresponding signature, it may contain the following values: UP (High gene/protein expression or increased cellular abundance or enhanced epigenetic modification), DN (Low gene/protein expression or reduced cellular abundance or attenuated epigenetic modifications), LOSS (deletion mutation), GAIN (gain mutation),Other. For example, the search/browse detail result for CD274 was “PROT_R_UP”, it can be interpreted that the protein level of CD274 was upregulated in immunotherapy response individuals.
Experimental clinical trial phase 1/2
Description Tumors of all (except two G1-L1) patients displayed ParvOryxdose-dependent positivity for H-1PV transcripts . And together with the results of preclinical virus distribution studies in rats, these data prove that H-1PV can cross the blood-brain/tumor barrier from the bloodinto the tumor.
PMID 28967558
Title Oncolytic H-1 Parvovirus Shows Safety and Signs of Immunogenic Activity in a First Phase I/IIa Glioblastoma Trial